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Abstract
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide,  making it  a  major  public  health issue.  The World Health Organiza‐
tion  (WHO)  estimates  a  worldwide  prevalence  of  3%.  Each  year,  three  to  four
million people are newly diagnosed with HCV, and it remains endemic in many
countries of the world. According to the WHO, there are at least 21.3 million HCV
carriers in Eastern Mediterranean countries, a figure close to the combined number
of estimated carriers in the Americas and Europe. The purpose of this chapter is
to give an overview and update in treatment of HCV patients by a broad search
of  published  literature  on  aspect  of  epidemiology,  natural  history,  risk  factors,
diagnosis and treatment of HCV, graded on the best available evidence. All that
to improve HCV patient care, and to promote and improve the multidisciplinary
care required in the treatment of these patients.
Keywords: HCV, hepatitis C treatment, sofosbuvir, Sovaldi, daclatasvir, ledipasvir/
sofosbuvir, Harvoni, Viekira Pak, Viekirax, Exviera, simeprevir
1. Introduction
Hepatitis C virus (HCV) infection is one of the main causes of progressive liver disease
worldwide,  making  it  a  major  public  health  issue.  World  Health  Organization  (WHO)
estimates indicate that more than 185 million people around the world have been infect‐
ed with HCV, of whom 350,000 die each year [1].
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
HCV induces chronic infection in up to 80% of infected individuals. One third of those who
become chronically infected are predicted to develop cirrhosis or hepatocellular carcinoma.
Despite its high prevalence, most people infected with the virus are unaware of their infection.
The purpose of this chapter is to give an overview on HCV and existing treatments and to
outline recent innovations in the treatment of HCV patients. To do this, a broad search of the
published literature has been undertaken. The search included epidemiology of HCV, its
natural history, the risk factors involved, as well as the diagnosis and treatment of HCV, all of
which have been graded on the best available evidence. The ultimate purpose is to improve
HCV patient care and to promote and encourage the multidisciplinary care required in the
treatment of these patients.
2. Epidemiology
In most countries, surveys undertaken to establish the prevalence of HCV have focused on
specific groups of individuals, for example, drug users, those indulging in high-risk sexual
behavior, and blood donors who are not representative of the general population. Conse‐
quently, global estimates of HCV prevalence in the year 2008 are still not accurate [2].
Overall, the available data suggest that 130-170 million individuals are infected with HCV
(approximately 2.2-3.0%) worldwide, with its highest prevalence occurring in Eastern Medi‐
terranean and African regions [2,3].
Previously undertaken analyses on global, regional, and country levels have mostly failed to
estimate the correct HCV disease burden with studies based on age distribution and active
infection. Most country-level studies have been carried out on the adult population; however,
when these estimates were applied to a country’s entire population, the disease burden was
probably overestimated. In addition, studies focused on anti-HCV (antibody positive) testing
overestimated the disease burden because they often included those subjects who have been
cured, either spontaneously or after treatment [4].
Globally, genotype 1 (G1) has been found to account for 46% of all anti-HCV infections among
adults, making it the most common, followed by G3 (22%), G2 (13%), G4 (13%), G6 (2%), and
G5 (1%). Undefined or combination genotypes accounted for 3% of total HCV infections [4].
Genotype 1b was the most common subtype, accounting for 22% of all infections. However,
significant regional, country, and local variations were found to exist. Infections in North
America, Latin America, and Europe were predominately G1 (62-71%), with G1b accounting
for 26%, 39%, and 50% of all cases, respectively. North Africa and the Middle East had a large
G4 population (71%), which was attributable to the high prevalence of G4 in Egypt. When
Egypt was excluded, genotype 4 accounted for 34% of all infections, and the genotype
distribution of this region was dominated by G1 (46%). Asia was predominately G3 (39%)
followed by G1 (36%), largely driven by the HCV infections in India and Pakistan. G1b
accounted for 25% of all infections in this region. In Australasia, G1 dominated (53%), followed
by G3 (39%). G1b was present in 16% of cases [4].
Recent Advances in Liver Diseases and Surgery80
3. Virology
The hepatitis C virus is a hepatotropic RNA virus of the genus Hepacivirus in the Flaviviridae
family, originally cloned in 1989 as the causative agent of non-A, non-B hepatitis [5,6,7]. HCV
is a positive-sense, single-stranded enveloped RNA virus approximately 9600 nucleotides in
length. Approximately 1012 viral particles are generated daily in chronically HCV-infected
patients [5,8]. The genome is organized to include nontranslated RNA segments (NTRs) at 5
and 3 ends and a single large open reading frame (ORF) encoding a giant 327 kDa polyprotein
that is processed by cellular and virally encoded proteases into three structural proteins (core,
E1, E2) and seven nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [9].
The HCV 5 NTR contains 341 nucleotides located upstream of the coding region and is
composed of four domains (numbered I to IV) with highly structured RNA elements, including
numerous stem loops and a pseudoknot. The 5 NTR also contains the internal ribosome entry
site (IRES), which initiates the cap-independent translation of HCV genome into a single
polyprotein by recruiting both viral proteins and cellular proteins such as eukaryotic initiation
factors (eIF) 2 and 3 [5].
The core protein is the viral capsid protein with a length of 191 amino acids (p21c). It can be
further cleaved to generate a smaller 179-amino-acid core protein (p19c). The core protein has
numerous functionalities involving RNA binding, immune modulation, cell signaling,
oncogenic potential, and autophagy [5,9,10]. E1 and E2 are the two viral envelope proteins that
surround the viral particles. p7 contains two transmembrane domains and is required for viral
assembly and release. NS2 is the viral autoprotease that likely contains at least four trans‐
membrane domains and plays a key role in viral assembly, mediating the cleavage between
NS2 and NS3 [5,9,11,12]. NS3 protease plays a critical role in HCV processing by cleaving
downstream of NS3 at four sites (between NS3/4A, NS4A/4B, NS4B/NS5A, and NS5A/NS5B)
[5,9]. NS4A is a cofactor for the NS3 protease, and NS5B is the viral RNA polymerase. The
functions of NS4B and NS5A are not totally clear, but they are probably involved in viral RNA
replication and pathogenesis. All of these HCV proteins are believed to form replication
complexes on intracellular membranes for either viral morphogenesis or RNA replication
[5,9,13-15].
4. Natural history and clinical presentation
Hepatitis C is a heterogeneous disease with considerable morbidity and mortality rates. More
than 80% of infected individuals develop chronic infection; the remaining 10-20% develop
spontaneous clearance with natural immunity. The acute infection has an incubation period
of 7 weeks (range, 4-20 weeks) and is symptomatic in only 20% of patients and rarely severely
icteric. Serum aminotransferase levels generally increase to more than 10 times the normal
range and go back to normal once the disease symptoms resolve themselves. HCV antibodies
usually develop at the time of onset of symptoms. HCV RNA appears even earlier, during the
incubation period, with an increase in titer at the time of the manifestation of symptoms, and
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then disappears once the disease disappears. Once acute HCV infection has established itself,
around 85% of patients develop chronic infection, which is generally asymptomatic. In these
patients, HCV RNA remains present and in approximately 75% of patients, alanine amino‐
transferases (ALT), and aspartate aminotransferases (AST) remain elevated at more than 1.5
times the upper normal limit. The course of chronic hepatitis C is variable, with vague,
intermittent, and nonspecific symptoms of chronic fatigue and malaise, which usually present
in less than 20% of patients. Extrahepatic manifestations of HCV, including glomerulonephritis
and cryoglobulinemia, can develop in a small percentage of patients. The development of
progressive liver injury, fibrosis, and cirrhosis can occur in 20% to 30% of chronically infected
patients over a period of 20-30 years. In patients presenting with chronic hepatitis C, fibrosis
progression is extremely variable over time and can be partially predicted based on the age of
the patient at infection, disease duration, liver histologic activity and stage of fibrosis, and ALT
profile. However, it is often difficult to predict clinical outcomes in individual cases. In patients
who have developed cirrhosis, the 5-year risk of decompensation is between 15% and 20% and
that of hepatocellular carcinoma around 10%. The relationship between virus load, HCV
genotype, quasi-species variability, and progression of liver disease is controversial. Acquired
infection after age 40 years, being male, excessive alcohol consumption, hepatitis B virus (HBV)
or HIV coinfection, steatosis, and immunosuppressed state have all been identified as cofactors
associated with progression of fibrosis and development of cirrhosis. Once cirrhosis develops,
symptoms are more common, and the signs of end-stage liver disease can appear, manifesting
themselves as jaundice, weakness, wasting, and gastrointestinal bleeding. The incidence of
developing hepatocellular carcinoma is 2-5% per year in patients with hepatitis C-related
cirrhosis. Thus, this important liver disease has protean manifestations but is often insidious
and can often lead to end-stage liver disease that needs liver transplantation, despite the
presence of few overt symptoms and signs of illness [16-20].
5. Risk factors
The risk factors for the transmission of HCV infection vary substantially between countries
and geographic regions. HCV is spread primarily by contact with blood and blood products.
With the introduction in 1991 of routine blood screening for HCV antibodies and improve‐
ments in the test in mid-1992, transfusion-related hepatitis C has virtually disappeared. Illicit
use of injectable drugs is currently the main source of HCV infections in most developed
countries (e.g., Western Europe, US) and is becoming a major source of infection in transitional
economy and developing countries, accounting for 40% or more of those infected. Of the
estimated 16 million people in 148 countries who actively inject drugs, 10 million are infected
with HCV [2,21,22]. In developing and transitional economy countries, the nosocomial
transmission of new HCV infections is a major problem because of the reuse of contaminated
or inadequately sterilized syringes and needles used in medical, paramedical, and dental
procedures, with an estimated 2.3-4.7 million new infections occurring each year [2,23-25]. In
patients on chronic hemodialysis, overall, the current prevalence of HCV is below 5% in most
of Northern Europe, around 10% in most of Southern Europe and the US, but between 10%
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and 50% and up to 70% in many parts of the developing world, including many Asian, Latin
American, and North African countries. It is important to emphasize that the prevalence of
HCV is highly variable from unit to unit within the same country, with recent reports from
some dialysis units in the US reporting a prevalence above 20% [26]. The risk of transmission
of HCV from a mother to her child occurs in 4-8% of births to women with HCV infection and
in 17-25% of births to women with HIV and HCV coinfection. The risk posed to the infant from
breastfeeding is negligible, and nonsexual intrafamilial transmission is very rare [27,28]. The
risk of heterosexual transmission is low, while recent data indicate that promiscuous male
homosexual activity is related to HCV infection [29]. Folk medicine practices, including
acupuncture and ritual scarification, as well as body piercing, tattooing, and commercial
barbering are potential modes for transmission of HCV infection when performed without
appropriate infection control measures [30,31].
6. Laboratory testing
6.1. Serologic and molecular assays
The test for anti-HCV is usually performed in the presence of an elevated ALT level and a
positive history of risk factors for HCV infection, or physical findings suggest the presence of
chronic liver disease. WHO recommends that HCV serology testing be performed on individ‐
uals who are part of a population with high HCV seroprevalence or who have a history of
HCV risk exposure and/or behavior rather than at the time of presentation with symptomatic
disease. The application of this recommendation will require taking into consideration which
populations meet these criteria. In some countries with a high seroprevalence of HCV or a low
level of infection control, HCV testing might be recommended for the general population.
Clearly, this would have significant resource implications [1]. Diagnosis of HCV infection is
based on the detection of anti-HCV antibodies by enzyme immunoassay and the detection of
HCV RNA by a sensitive molecular method, ideally a real-time PCR assay. These assays have
no role in the assessment of disease severity or its prognosis [32,33]. Genotyping is useful in
epidemiological studies, and also in clinical management, for predicting the likelihood of
response and determining the optimal duration of therapy. Several commercial assays are
available to determine HCV genotypes using direct sequence analysis of the 5 noncoding
region, which includes Trugene 5 NC HCV genotyping kit, reverse hybridization analysis
using genotype-specific oligonucleotide probes located in the 5 noncoding region, INNO-LiPa
HCV II, and Versant HCV Genotyping Assay 2.0 [34,35].
6.2. Defining disease severity
Laboratory tests that are commonly obtained following the initial diagnosis of chronic hepatitis
C include liver enzymes and function tests, a complete blood cell count, tests for coinfection
with HBV or HIV, tests for immunoglobulin G antibody to hepatitis A virus (anti-HAV) to
determine if immunity is present or if vaccination is recommended, and antinuclear antibody
to exclude coexistent autoimmune hepatitis.
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Elevated blood levels of liver enzymes ALT and AST occur when the membrane of the liver
cells is  damaged and liver enzymes leak into the blood stream, thus indicating ongoing
liver injury. The degree of elevation of liver enzymes present in the blood correlates with
the severity of liver cell  injury. However, blood levels of liver enzymes do not correlate
with the degree or severity of hepatic fibrosis. The important tests that reflect liver synthetic
function are serum bilirubin,  albumin,  and international  normalized ratio  (INR).  Abnor‐
mal  serum  albumin,  bilirubin,  or  prothrombin  time  may  be  seen  in  the  setting  of  im‐
paired hepatic synthetic function. Some models used to evaluate liver disease severity are
helpful  for  the  assessment  of  liver  function,  for  example,  the  model  for  end-stage  liver
disease (MELD). The MELD score was adopted by UNOS in 2002 for use in deceased donor
liver allocation for adults with cirrhosis. MELD is a prospectively developed and validat‐
ed chronic liver disease severity scoring system that uses a patient’s laboratory values for
serum bilirubin, serum creatinine, and INR to predict a 3-month survival [36]. The MELD
equation that is currently used by UNOS for prioritizing allocation of deceased donor livers
for transplantation is as follows: MELD = 3.8*loge(serum bilirubin [mg/dL]) + 11.2*loge(INR)
+ 9.6*loge(serum creatinine [mg/dL]) + 6.4. Patients with the combination of serum creati‐
nine ≤1 mg/dl, serum bilirubin ≤1 mg/dl, and INR ≤1 will receive the minimum score of 6
MELD points. In addition, UNOS has set an upper limit for the MELD score at 40 points.
However,  there  is  no  need  to  go  through  the  above  time-consuming  equation  because
several online tools are available for calculating the MELD score [37-39].
7. Tests of fibrosis
7.1. Noninvasive laboratory tests
Noninvasive tests of hepatic fibrosis are used for the staging of fibrosis in patients with chronic
liver disease. The tests are often used to differentiate patients with significant fibrosis (F2 to
F4) from those with minimal or no fibrosis (F0 to F1). There are four commercial serum marker
systems that have been validated: FibroTest/FibroSure (marketed in the United States by
LabCorp), Hepascore (Quest Diagnostics), FibroSpect (Prometheus Corp), and the European
Liver Fibrosis Study Group panel (not available in the United States). In addition, the aspartate
aminotransferase-to-platelet ratio (APRI) has also been studied. The APRI has the advantage
of being easily calculated using data available from routine laboratory tests.
All the serum tests have limitations: (a) they typically reflect the rate of matrix turnover, not
deposition, and thus tend to be more elevated when there is high inflammatory activity. By
contrast, extensive matrix deposition can go undetected if there is minimal inflammation. (b)
None of the markers are liver specific, and concurrent sites of inflammation may contribute to
serum levels. (c) Serum levels are affected by clearance rates, which may be impaired due to
either sinusoidal endothelial cell dysfunction or impaired biliary excretion. (d) They are
surrogates, not biomarkers [40].
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7.2. Elastogram (Fibroscan)
Fibroscan can quantify fibrosis in the liver by means of elastography. Tissue elasticity is
acquired through pulse-echo ultrasound, measuring shear wave velocity, the S-wave. The
wave travels faster in less elastic and stiff livers. Results of liver elasticity are expressed in
kilopascals (kPa). The scan can be performed easily; it is inexpensive and produces no side
effects. The position of the patient is similar to when performing a liver biopsy, that is, on the
back, with the right hand under the head. Patients only feel the probe pressure in the intercostal
space without anticipated pain. It is possible to measure liver elasticity from different angles
in the right as well as the left lobe. A liver stiffness measurement using Fibroscan is reprodu‐
cible and independent of the operator, and explores a volume of liver parenchyma, which can
be approximated to a cylinder of 1 cm in diameter and 4 cm in length. This volume is 100 times
larger than the biopsy specimen volume and is thus much more representative of the entire
hepatic parenchyma. Some extensive studies have demonstrated that the measurement of liver
stiffness with Fibroscan is a good alternative for liver biopsy. The amount of fibrosis can be
quantified very easily and reliably and is feasible in more than 95% of the patients. Obesity,
ascites, and narrow intercostal spaces are physiological boundaries that can hamper the
accuracy of the test. Acute hepatitis and liver congestion as in cardiac failure can cause false
high scores, and they need to be ruled out before carrying out Fibroscan. Sometimes it may be
virtually impossible to take measurements in such patients [41, 42]. Fibroscan value ranged
from 2.4 to 75.5 kPa with a cutoff value of 7.1 kPa for F ≥ 2, 9.5 kPa for F ≥3, and 12.5 kPa for F
= 4 (according to Metavir histological classification system) [41, 43]. One of the studies
comparing elastography to histological examination on 327 patients concluded that liver
stiffness measurements and fibrosis grades correlated well, with increasing reliability in more
extensive fibrosis (F ≥ 3) or cirrhosis. It was impossible to determine a cutoff value to differ‐
entiate between F0 and F1 by Fibroscan [41,44].
7.3. Liver biopsy
Percutaneous liver biopsy is the gold standard for grading and staging of liver disease, which
can help to determine the extent of progress of hepatic fibrosis and inflammation. It is
important in clinical practice, where it may reflect the severity of liver disease and predict
response to treatment. Liver biopsy is an invasive procedure associated with discomfort and,
in rare cases, with serious complications. The accuracy of liver biopsy is limited and prone to
sampling error and interpretational variability. Although this procedure continues to be
recommended, current practice is changing for two main reasons: first, treatment is being
shown to be more effective, and second, biochemical tests, serological tests, and elastograms
can all provide a great deal of information on disease progression. Pathologists can increase
the importance and utility of liver biopsy in chronic hepatitis C, providing information not
only on the stage of fibrosis and necro-inflammatory activity but also on the grade of steatosis
and iron accumulation, which are implicated in disease progression. Moreover, other diseases,
such as steatohepatitis and hereditary hemochromatosis can be identified by liver biopsy.
Nevertheless, the use of serological and radiological tests will reduce the indications for liver
biopsy [45].
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8. Hepatitis C treatments
The ultimate goal of treatment in patients with chronic HCV is to eradicate HCV RNA, which
is associated with decreases in all-cause mortality, liver-related death, need for liver trans‐
plantation, hepatocellular carcinoma rates, and liver-related complications.
Since interferon-alpha (IFN-α) was first introduced for treatment of non-A, non-B hepatitis
1990, therapy for patients with chronic HCV has improved dramatically. Sustained virological
response rates (SVRs) have increased from 5% to 10% with standard interferon therapy, to over
40% when standard interferon is combined with ribavirin. The modification of interferon
(pegylation) to improve its pharmacokinetics has further increased rates of SVR. Two types of
pegylated interferon, pegylated interferon α2a and pegylated interferon α2b,which differ in
their pharmacokinetics and chemical properties, were approved by the FDA in 2001. Treatment
with combined pegylated interferon and ribavirin may result in SVR in 42% to 52% of genotype
1 infected patients, 70% to 80% of genotype 2 or 3 infected patients, and 54-68% of genotype 4
infected patients [46,47].
The landscape of treatment for HCV infection has evolved substantially since the introduction
of highly effective HCV protease inhibitor therapies, namely, boceprevir and telaprevir, in
2011. Both drugs were approved as directly acting antiviral treatments for use in HCV
genotype 1 infection, in combination with pegylated interferon and ribavirin. These NS3/4A
protease inhibitors have been shown to substantially increase rates of SVR to 59-75% in both
treatment-naive and previously treated patients, compared with dual therapy [48-52].
Although their development was a major advance, both agents are associated with significant
toxicity, numerous drug-drug interactions, and low response rates in those patients with
cirrhosis and nonresponders to previous treatment. In addition, boceprevir and telaprevir
required the addition of pegylated interferon and ribavirin for 24 to 48 weeks, which markedly
increased the overall cost of therapy, and are associated with the emergence of resistance-
associated variants in the majority of patients who fail treatment [53].
In 2013 and 2014, the FDA approved new direct acting antiviral treatments, including second
generation protease inhibitors, NS5A inhibitors, and NS5B RNA-dependent RNA polymerase
inhibitors with HCV eradication rates of >95%.
The eradication of HCV RNA is predicted by the achievement of SVR and defined by the
absence of HCV RNA by polymerase chain reaction three to 6 months after stopping treatment.
An SVR is associated with a 99% chance of being HCV RNA negative during long-term follow-
up and can therefore be considered an indication of a cure of the HCV infection. With the
growing availability of highly effective interferon-free regimens for HCV infection, a curative
all-oral treatment is becoming a possibility for the vast majority of patients. The second-
generation protease inhibitors that have been approved for treatment of HCV and are available
in the market are simeprevir, sofosbuvir, ledipasvir/sofosbuvir, daclatasvir, and the combi‐
nation of ombitasvir-paritaprevir-ritonavir and dasabuvir. Trials are still ongoing on other
new products, many of which are expected to appear in the near future.
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8.1. Simeprevir (Olysio®, Janssen Therapeutics)
This is the first available second-generation protease inhibitor (NS3/4A protease inhibitor)
indicated for the treatment of chronic hepatitis C infection as a component of a combination
antiviral treatment regimen [54]. Simeprevir is available in 150 mg capsules to be taken orally
once daily with food. The elimination of simeprevir is by the liver, and no dose adjustment is
required in the setting of renal impairment [55]. Simeprevir is not recommended in patients
with hepatic impairment Child-Pugh Class B and C because of two- to five-fold increases in
exposure. In general, simeprevir is well tolerated. Its most common adverse effects are rash
(including a potentially serious photosensitivity reaction), pruritus, and nausea. The photo‐
sensitivity reaction that related to simeprevir usually occurs during the first 4 weeks of therapy
but can develop at any time on treatment. Patients taking simeprevir may experience transient
increases in serum bilirubin levels that peak at week 2 of treatment, but these are typically mild
in severity and not associated with elevated hepatic aminotransferase levels [56,57]. The
coadministration of simeprevir with substances that are moderate or strong inducers or
inhibitors of cytochrome P450 3A (CYP3A) is not recommended, as this may lead to signifi‐
cantly lower or higher exposure of simeprevir, respectively, which may result in reduced
therapeutic effect or adverse reactions. A number of compounds are contraindicated in
patients receiving simeprevir, including the following:
1. Antibiotics (erythromycin, clarithromycin, telithromycin, rifampin, rifabutin, rifapentine)
2. Systemically administered antifungals (itroconazole, ketoconazole, voriconazole, posa‐
conazole, fluconazole)
3. Anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin)
4. Systemically administered dexamethasone
5. Herbal products (milk thistle, St. John’s wort)
6. A number of antiretroviral drugs, including cobicistat-based regimens, efavirenz,
delavirdine, etravirine, nevirapine, ritonavir, and any HIV protease inhibitor, boosted or
not by ritonavir.
Simeprevir is safe in patients using immunosuppressants, such as cyclosporine and tacrolimus,
with no dose adjustment, and safe in those using lamivudine, emtricitabine, tenofovir,
abacavir, raltegravir, maraviroc, and rilpivirine. The dose of simeprevir needs adjustment with
some antiarrhythmics, warfarin, HMG Co-A reductase inhibitors, sedative/anxiolytics, and
calcium channel blockers [58-64].
8.2. Sofosbuvir (Sovaldi®, Gilead Sciences)
This is an HCV nucleotide analog NS5B polymerase inhibitor indicated for the treatment of
chronic hepatitis C infection as a component of a combination antiviral treatment regimen.
Sofosbuvir is available as a 400-mg tablet. The recommended dose of sofosbuvir is 400 mg
taken orally once daily, with or without food, regardless of the patient’s genotype or prior
hepatitis C treatment experience. No dose adjustment is needed for mild-to-moderate renal
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impairment or with mild, moderate, or severe hepatic impairment. Currently, no dose
recommendation can be given for patients with severe renal impairment (estimated glomer‐
ular filtration rate <30 ml/min) or with end-stage renal disease due to higher exposures (up to
20-fold) of the predominant sofosbuvir metabolite. Sofosbuvir has pan-genotypic HCV activity
and is effective in treatment-naive, treatment-experienced, and HIV-coinfected patients with
compensated cirrhosis, and in patients with hepatocellular carcinoma meeting Milan criteria
awaiting liver transplantation. Sofosbuvir has been very well tolerated in clinical trials. The
most common adverse effects (≥20%) observed with sofosbuvir, when used in combination
with ribavirin, have been fatigue and headaches. The most common adverse events (≥20%)
observed in combination with pegylated IFN-α and ribavirin were fatigue, headaches, nausea,
insomnia, and anemia. Drugs that are potent P-glycoprotein (P-gp) inducers significantly
decrease sofosbuvir plasma concentrations and may lead to a reduced therapeutic effect. Thus,
sofosbuvir should not be administered with other known inducers of P-gp, such as rifampin,
carbamazepine, phenytoin or St. John’s wort [62,65-77].
8.3. Ledipasvir-sofosbuvir (Harvoni®, Gilead Sciences)
The nucleotide polymerase inhibitor sofosbuvir (400 mg) has been combined with the NS5A
inhibitor ledipasvir (90 mg) in a single tablet regimen (SOF/LDV) administered once daily. The
combination of ledipasvir-sofosbuvir has primarily been studied as an all-oral (interferon-free)
combination regimen in treatment-naive and treatment-experienced patients with genotype 1
chronic HCV infection. For patients with mild to moderate renal impairment, no dosage
adjustment of ledipasvir/sofosbuvir is recommended. Severe renal impairment (estimated
glomerular filtration rate <30 mL/min) does not substantially affect the pharmacokinetics of
ledipasvir, but because levels of sofosbuvir and its metabolite accumulate in the setting of
severe renal impairment, the combination should not be used in such settings pending further
data. Thus, no dosage recommendation has been given for patients with severe renal impair‐
ment or end-stage renal disease requiring dialysis. Available data from clinical trials have
shown that the combination of ledipasvir and sofosbuvir has been very well tolerated. The
most commonly reported adverse effects are fatigue and headaches. Ledipasvir, like sofosbu‐
vir, is a substrate of the P-gp drug transporter, so drugs that are potent intestinal P-gp inducers
may decrease ledipasvir levels. Thus, the coadministration of ledipasvir-sofosbuvir is not
recommended with rifampin, St. John’s wort, carbamazepine, phenytoin, phenobarbital,
oxcarbazepine, or tipranavir/ritonavir. In addition, ledipasvir is an inhibitor of P-gp and may
increase absorption of P-gp substrates. The coadministration of ledipasvir with tenofovir
results in increased levels of tenofovir, particularly in the presence of other boosting agents.
Until further data are available, ledipasvir-sofosbuvir should not be used with the combination
of elvitegravir, cobicistat, emtricitabine, and tenofovir, and should only be used cautiously
with regimens that contain tenofovir and a ritonavir-boosted protease inhibitor [73,78-83].
8.4. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir (Viekira Pak®, AbbVie Inc)
The Viekira Pak is an all-oral regimen comprised of four medications: ombitasvir, paritaprevir,
ritonavir, and dasabuvir. This regimen can be used with or without ribavirin. In the Viekira
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Pak, ombitasvir, paritaprevir, and ritonavir (Viekirax®) are combined as a fixed-dose tablet
and the dasabuvir (Exviera®) is a separate tablet. Ombitasvir, paritaprevir, and dasabuvir are
direct-acting antivirals (DAAs) that directly interfere with HCV replication. Ombitasvir is an
NS5A inhibitor with potent pan-genotypic picomolar antiviral activity, paritaprevir is an
inhibitor of the NS3/4A serine protease, and dasabuvir is a nonnucleoside NS5B polymerase
inhibitor. Ritonavir is a CYP3A inhibitor, and it boosts the blood levels of paritaprevir.
Paritaprevir (150 mg), ritonavir (100 mg), and ombitasvir (25 mg) are coformulated in a single
tablet taken as two tablets once daily. This tablet is combined with dasabuvir (250 mg) taken
as one tablet twice daily. The regimen ombitasvir-paritaprevir-ritonavir plus dasabuvir is FDA
approved for the treatment of chronic hepatitis C genotype 1, including those with compen‐
sated cirrhosis. The regimen ombitasvir-paritaprevir-ritonavir plus dasabuvir, with or without
ribavirin, has primarily been studied as an all-oral (interferon-free) regimen in treatment-naive
and treatment-experienced patients with genotype 1a or 1b chronic HCV infection, including
those with compensated cirrhosis, HIV coinfection, and after receipt of liver transplantation.
For patients with mild hepatic impairment (Child-Pugh A), no dosage adjustment is required
for ombitasvir-paritaprevir-ritonavir and dasabuvir; however, this regimen is not recom‐
mended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated
with severe hepatic impairment (Child-Pugh C). For patients with mild, moderate, or severe
renal insufficiency, no dosing adjustment is required for the regimen ombitasvir-paritaprevir-
ritonavir and dasabuvir; this regimen, however, has not been adequately studied in patients
with end-stage renal disease on dialysis. Available data from clinical trials have demonstrated
excellent tolerance with the ombitasvir-paritaprevir-ritonavir and dasabuvir regimen. The
most common (greater than 10%) adverse effects observed in clinical trials when used without
ribavirin have been fatigue, nausea, pruritus, other skin reactions, insomnia, and asthenia. The
concomitant use of ombitasvir-paritaprevir-ritonavir and dasabuvir with ethinyl estradiol-
containing medications (e.g., oral contraceptives) can result in significant elevations in hepatic
aminotransferase levels; accordingly, patients should discontinue any ethinyl estradiol-
containing medications prior to starting ombitasvir-paritaprevir-ritonavir and dasabuvir. The
use of ombitasvir-paritaprevir-ritonavir plus dasabuvir can potentially cause significant drug-
drug interactions, primarily because of the potent ritonavir inhibition of CYP3A4 enzyme.
There are a number of medications contraindicated to use concomitantly with ombitasvir-
paritaprevir-ritonavir and dasabuvir, like carbamazepine, phenytoin, phenobarbital, gemfi‐
brozil, rifampin, ergotamine, oral contraceptives containing ethinyl estradiol, lovastatin,
simvastatin, sildenafil, orally administered midazolam, and St. John’s wort. The efficacy of
ombitasvir-paritaprevir-ritonavir plus dasabuvir is not known for patients with prior virologic
failure and resistance with treatment that included another NS3/4A inhibitor, NS5A inhibitor,
or NS5B inhibitor [84-90].
8.5. Daclatasvir (Daklinza®, Bristol-Myers Squibb)
The European Commission approved daclatasvir, a potent pan-genotypic NS5A replication
complex inhibitor (in vitro), at the end of August 2014. Daclatasvir should be administered at
the dose of 60 mg (one tablet) once per day. It is well tolerated overall. Dose adjustments are
not needed in patients with Child B or C disease. Daclatasvir can be used in combination with
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other drugs for the treatment of chronic HCV infection genotypes 1, 2, 3, and 4 in adults.
Daclatasvir, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen
that provided cure rates of more than 95% in clinical trials, including in patients with advanced
liver disease, genotype 3, and those who have previously failed treatment with protease
inhibitors. Across clinical studies, daclatasvir-based regimens have been generally well
tolerated, with low discontinuation rates. The most common adverse effects with daclatasvir
when used in combination with other drugs are fatigue, headaches, and nausea. Little
information has been released on daclatasvir drug-drug interactions. Daclatasvir is a substrate
of CYP34A and a substrate and inhibitor of P-gp. The daclatasvir dose should be adjusted to
30 mg daily in HIV-infected patients receiving atazanavir/ritonavir and to 90 mg daily in those
receiving efavirenz. No dose adjustment is needed with tenofovir. No information on other
antiretroviral drugs is available yet. No dose adjustments are required with cyclosporine or
tacrolimus. Total daclatasvir AUC is decreased by 40% and 43% in patients with mild or
moderate liver impairment, respectively. However, the unbound pharmacologically active
fraction is unchanged; thus, dose adjustment is not needed in patients with liver impairment
[77,91,92].
The direct acting antiviral treatment is usually used in combination for HCV treatment
according to genotypes and stage of liver disease, and the patient is either naive or has previous
experience of treatment.
The following recommendations can be used for treatment of HCV according to genotypes
with a high response rate (>90%):
1. HCV genotype 1 [91,93]
a. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks.
The addition of daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg])
is recommended in patients with cirrhosis. The duration of treatment extended to 24
weeks in patients with contraindications to ribavirin.
b. Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir
(25 mg) plus twice-daily dosed dasabuvir (250 mg) and daily weight-based ribavirin
(1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12 weeks (no cirrhosis) or 24 weeks
(cirrhosis) for treatment of both naive and prior pegylated interferon and ribavirin
treatment failure, in patients with HCV genotype 1a infection.
c. Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir
(25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 weeks for treatment-naive
and prior pegylated interferon and ribavirin treatment failure, in patients with HCV
genotype 1b infection. The addition of daily weight-based ribavirin (1000 mg [<75 kg]
to 1200 mg [>75 kg]) is recommended in patients with cirrhosis.
d. Daily fixed-dose combination of daclatasvir 60 mg and sofosbuvir 400 mg for 12
weeks. The addition of daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) is recommended in patients with cirrhosis. The duration of treatment
extended to 24 weeks in patients with contraindications to ribavirin.
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e. Daily sofosbuvir (400 mg) plus simeprevir (150 mg) for 12 weeks. The addition of
daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg]) is recommended
in patients with cirrhosis. The duration of treatment extended to 24 weeks in patients
with contraindications to ribavirin.
f. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) plus weekly pegylated interferon for 12 weeks.
2. HCV genotype 2 [91,93]
a. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) for 12 weeks; extending duration of treatment to 16-20 weeks is recom‐
mended in patients with cirrhosis and those in whom prior pegylated interferon and
ribavirin treatment has failed.
b. Daily sofosbuvir (400 mg) and daclatasvir (60 mg) for 12 weeks in cirrhotic or
treatment-experienced patients.
c. Retreatment with daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75
kg] to 1200 mg [≥75 kg]) plus weekly pegylated interferon for 12 weeks is an alter‐
native in patients where prior pegylated interferon and ribavirin treatment has failed.
3. HCV genotype 3
When pegylated interferon and ribavirin was the treatment for HCV, the same regimen was
administered to all subjects, and patients were defined as easy or difficult to treat according
to viral genotype. HCV genotypes 1 and 4 were considered to be difficult to treat, and HCV
genotypes 2 and 3 were considered to be easy to treat. The SVR rates in the latter group were
above 80% with shorter treatment [94,95]. The availability of interferon-free regimens has
confirmed that HCV genotype 2 patients are easy to treat, while the paradigm for HCV
genotype 3 patients has been reversed compared to “older, difficult-to-treat” HCV genotype
1 patients. In fact, today, with available direct acting antiviral drugs, patients with HCV
genotype 3 are the most difficult to treat patients. In large studies on HCV genotype 3 to assess
the effectiveness of 12-16 weeks treatment with sofosbuvir and ribavirin, it has been shown
that 12 weeks of therapy in treatment-naive patients resulted in an SVR in 61% and 34% of
noncirrhotic and cirrhotic patients, respectively. Moreover, the SVR rates in experienced
noncirrhotic patients were 37% at 12 weeks and were increased to 63% in patients with 16
weeks’ course [70,67,95]. Extended treatments to 24 weeks of sofosbuvir and ribavirin were
evaluated in the valence trial, resulting in an overall SVR rate of 83%. In particular, this was
the result of higher SVR rates in treatment-naive (93% and 92% in patients without and with
cirrhosis, respectively) and experienced patients without cirrhosis (87%), while rates were
lower in experienced (61%) patients with cirrhosis [80,95,96]. The Lonestar-2 study tested
treatment with pegylated interferon/sofosbuvir/ribavirin for 12 weeks in treatment-experi‐
enced HCV-2 and HCV-3 patients. The SVR in HCV genotype 3 patients was 83% with no
difference in relation to baseline cirrhosis (SVR 83% vs. 83%, respectively) [69]. The second
study tested a combination of daclatasvir/sofosbuvir, resulting in an SVR of 89% of 18
treatment-naive patients with HCV genotype 3 [97].
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The following treatment options with similar efficacy can be used in genotype 3 naive patients
and patients in whom prior pegylated interferon and ribavirin treatment has failed [91-93,97]:
a. Daily fixed-dose combination of daclatasvir 60 mg and sofosbuvir 400 mg for 12 weeks in
patients without cirrhosis. Daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75
kg]) is added to regimen to treat naive and treatment-experienced patients with cirrhosis
for 24 weeks.
b. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75
kg]) for 24 weeks.
c. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75
kg]) plus weekly pegylated interferon for 12 weeks is an acceptable regimen for interferon-
eligible, treatment-naive patients with HCV genotype 3 infection.
4. HCV genotype 4 [70,91,93,98-101]
a. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks.
The addition of daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg])
is recommended in patients with cirrhosis. The duration of treatment extended to 24
weeks in patients with contraindications to ribavirin.
b. Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir
(25 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12
weeks for treatment of both naive and prior pegylated interferon and ribavirin
treatment failure, and treatment can be extended to 24 weeks in patients with
cirrhosis.
c. Daily fixed-dose combination of daclatasvir 60 mg and sofosbuvir 400 mg for 12
weeks. The addition of daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) is recommended in patients with cirrhosis. The duration of treatment
extended to 24 weeks in patients with contraindications to ribavirin.
d. Daily sofosbuvir (400 mg) plus simeprevir (150 mg) for 12 weeks. The addition of
daily weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg]) is recommended
in patients with cirrhosis. The duration of treatment extended to 24 weeks in patients
with contraindications to ribavirin.
e. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) plus weekly pegylated interferon for 12 weeks.
5. HCV genotype 5 [91,93]
A few data are available to help guide decision making for patients infected with HCV
genotype 5 or 6, but currently the following are the recommendations until more data are
available:
a. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) plus weekly pegylated interferon for 12 weeks
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b. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) for 24 weeks
c. Weekly pegylated interferon plus weight-based ribavirin (1000 mg [<75 kg] to 1200
mg [>75 kg]) for 48 weeks is an alternative regimen for interferon-eligible, treatment-
naive patients.
6. Genotype 6 [91,93]
a. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks
b. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) plus weekly pegylated interferon for 12 weeks
c. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) for 24 weeks
Due to the very high efficacy and the excellent tolerability of IFN-free regimens, response-
guided shortening or prolongation of therapy have not been studied and, indeed, may not be
needed to achieve high cure chances in the individual patient. However, given the high costs
of direct antiviral drugs, HCV RNA testing during treatment may be helpful for surveillance
of compliance and motivation of patients. HCV RNA should be measured at baseline, week 2
(assessment of adherence), week 4, week 12 or 24 (end of treatment), and 12 or 24 weeks after
the end of therapy [102].
9. Treatment of special populations with direct acting antiviral regimens
9.1. HIV/HCV-coinfected individuals
Hepatitis C virus (HCV)-related liver disease is a major source of mortality in HIV-infected
patients. Approximately one third of all patients with HIV are coinfected with HCV. Patients
coinfected with HIV/HCV have shown lower rates of SVR with pegylated-interferon and
weight-based ribavirin as well as more rapid progression of fibrosis than those with HCV
monoinfection [103]. HIV/HCV-coinfected persons should be treated and retreated the same
as persons without HIV infection, after recognizing and managing interactions with antire‐
troviral medications. Based on AASLD/IDSA/IAS-USA [93], the following precautions should
be considered:
a. Antiretroviral treatment interruption in patients with HIV/HCV is not recommended to
allow HCV therapy.
b. Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) should not be used
with cobicistat and elvitegravir, pending further data.
c. Sofosbuvir or ledipasvir/sofosbuvir should not be used with tipranavir because of the
potential of this antiretroviral drug to induce P-gp.
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d. Fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg)
plus twice-daily dosed dasabuvir (250 mg) should not be used with efavirenz, rilpivirine,
darunavir, or ritonavir-boosted lopinavir.
e. Paritaprevir/ritonavir/ombitasvir with or without dasabuvir should not be used in HIV/
HCV-coinfected individuals who are not taking antiretroviral therapy.
f. Simeprevir should not be used with efavirenz, etravirine, nevirapine, cobicistat, or any
HIV protease inhibitors.
g. Ribavirin should not be used with didanosine, stavudine, or zidovudine.
The management  of  HIV/HCV patients  should take  place  in  collaboration with  an HIV
practitioner.  Special  precautions  should  be  taken when prescribing  DAAs in  patient  on
AIDS treatment  to  avoid  under-  or  overdose  in  such  patients  as  a  result  of  drug-drug
interactions. For example, ledipasvir increases tenofovir levels,  concomitant use needs to
be avoided in patients with CrCl below 60 mL/min. Because potentiation of this effect is
expected when tenofovir is used with ritonavir-boosted HIV protease inhibitors, ledipas‐
vir  should  be  avoided  with  this  combination.  Paritaprevir/ritonavir/ombitasvir  plus
dasabuvir should be used with antiretroviral drugs with which it does not have substan‐
tial  interactions  like  atazanavir,  enfuvirtide,  lamivudine,  emtricitabine,  tenofovir,  and
raltegravir (and probably dolutegravir) [93].
The dose of ritonavir used for boosting of HIV protease inhibitors may need to be adjusted (or
held) when administered with paritaprevir/ritonavir/ombitasvir plus dasabuvir, and then
restored when HCV treatment is completed. The HIV protease inhibitor should be adminis‐
tered at the same time as the fixed-dose HCV combination. Simeprevir should only be used
with antiretroviral drugs, with which it does not have clinically significant interactions like
raltegravir (and probably dolutegravir), rilpivirine, maraviroc, enfuvirtide, tenofovir, emtri‐
citabine, lamivudine, and abacavir [93].
9.2. Patients with decompensated cirrhosis
In patients with Child-Pugh B or C cirrhosis awaiting transplantation, antiviral therapy may
be offered on an individual basis in experienced centers, pending the presentation of more
data in this population. It is possible that patients with decompensated cirrhosis who are not
on a transplant list could benefit from an interferon-free treatment regimen. However, the
safety and efficacy of an interferon-free regimen in patients with decompensated cirrhosis not
on a transplant waiting list is unknown, and the impact on mortality in this group is not yet
established. According to AASLD/IDSA/IAS-USA [93] and EASL recommendations on
treatment of hepatitis C 2015 [91], the following medications can be used with high virological
response >90%:
a. Decompensated cirrhosis: genotypes 1 and 4
• Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) and ribavirin
(initial dose of 600 mg, increased as tolerated) for 12 weeks is recommended for patients
with decompensated cirrhosis.
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• For patients with decompensated cirrhosis and anemia or ribavirin intolerance, daily
fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks is
recommended.
• For patients with decompensated cirrhosis in whom prior sofosbuvir-based treatment
has failed, daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) and
ribavirin (initial dose of 600 mg, increased as tolerated) for 24 weeks is an alternative
regimen.
• Daily fixed-dose combination of sofosbuvir (400 mg), ribavirin (initial dose of 600 mg,
increased as tolerated), and daclatasvir 60 mg for 12 weeks before liver transplantation
is recommended for patients with decompensated cirrhosis.
b. Decompensated cirrhosis: genotypes 2 and 3
• Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg
[>75 kg]) (doses need to be adjusted according to the patient’s creatinine clearance rate
and hemoglobin level) for up to 48 weeks is recommended for patients with HCV
genotype 2 or 3 who have decompensated cirrhosis.
9.3. Patients with HCV recurrence post liver transplantation
Patients with posttransplant recurrence of HCV infection should be considered for therapy.
Significant fibrosis or portal hypertension 1 year after transplantation could predict rapid
disease progression and graft loss and could indicate the need for more urgent antiviral
treatment. Interferon-free DAA can cure most liver transplant recipients with recurrent
hepatitis C, including a majority of those with severe post-transplant liver disease. In addition
to viral suppression, treatment also improves liver function. DAA treatment is generally safe
and well tolerated, certainly more so than interferon-based therapy, although anemia remains
a concern for people taking ribavirin. Drug-drug interactions may be important in the
posttransplant setting. No clinically significant drug-drug interactions have been found
between sofosbuvir, simeprevir, or daclatasvir on the one hand, and cyclosporine and
tacrolimus on the other hand.
The following options proved to be useful in post-liver transplantation patients according to
genotypes, with high virological response, waiting more data in near future [91,93,104,105]:
a. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with weight-
based ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12 weeks is recommended for
patients with HCV genotype 1 or 4 infection in the allograft, including compensated
cirrhosis.
b. Patients who are ribavirin intolerant or ineligible, ledipasvir (90 mg)/sofosbuvir (400 mg)
usually extended for 24 weeks in patients with HCV genotype 1 or 4 infection.
c. Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight-based
ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12 to 24 weeks in patients with
genotype 1 or 4 infection in the allograft, including compensated cirrhosis.
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d. Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25
mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based ribavirin (1000 mg [<75
kg] to 1200 mg [>75 mg]), in the allograft, without cirrhosis, for 24 weeks in patients with
HCV genotype 1 infection.
e. Daily sofosbuvir (400 mg) plus daclatasvir (60 mg) with or without weight-based ribavirin
(1000 mg [<75 kg] to 1200 mg [>75 kg]) for 24 weeks for patients with HCV genotypes 1,
3, 4, 5, and 6 in the allograft, including those with compensated and decompensated
cirrhosis is another combination with high virological response and improvement of liver
function.
f. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75
kg]) for 24 weeks is recommended for patients with HCV genotype 2 in the allograft,
including compensated cirrhosis.
g. Daily sofosbuvir (400 mg) and weight-based ribavirin (1000 mg [<75 kg] to 1200 mg [>75
kg]) for 24 weeks is recommended as alternative for treatment patients with HCV
genotype 3 infection in the allograft, including compensated and decompensated cirrho‐
sis.
9.4. Patients with renal impairments
For patients with creatinine clearance of >30 mL/min, no dosage adjustment is required when
using simeprevir, sofosbuvir, daclatasvir, fixed-dose combination of ledipasvir (90 mg)/
sofosbuvir (400 mg), or fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/
ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) to treat patients with HCV
infection. Simeprevir, daclatasvir, and the combination of paritaprevir, ritonavir, ombitasvir
and dasabuvir are cleared by hepatic metabolism and can be used in patients with severe renal
impairment [91].
EASL Recommendations on Treatment of Hepatitis C 2015 and AASLD/IDSA/IAS-USA 2014
guidelines on HCV treatment do not recommend sofosbuvir in patients with creatinine
clearance of <30 mL/min or with ESRD until more data are available [91,93].
9.5. Patients with acute HCV infection
When the efficacy of the treatment of acute HCV infection was superior to the treatment of
chronic infection, there was a strong impetus to identify and treat acute HCV infection with
interferon [106]. The current availability of interferon-sparing HCV treatments that have high
safety and efficacy reduces the advantage of early treatment of HCV infection. Until data
documenting the efficacy and safety of treatment of acute hepatitis C with direct acting
antiviral drugs are available, monitoring for spontaneous clearance for minimum of 6 months
before initiating treatment is required. When a decision is made to treat patients after 6 months
of acute infection, then the patient can be treated as described for chronic HCV [93].
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10. Conclusion
Chronic hepatitis C in the presence of the new direct-acting antiviral drugs became a curable
disease, with a sustained virological response of more than 90%. The second-generation
protease inhibitors that have been approved for treatment of HCV and are available in the
market are simeprevir, sofosbuvir, ledipasvir/sofosbuvir, daclatasvir, and the combination of
ombitasvir-paritaprevir-ritonavir and dasabuvir. The cost of these new agents prevents
universal delivery of medications and prioritization of treatment should be given to patients
who are in need of immediate care like those with advanced liver disease and extrahepatic
complications. Trials are still ongoing with other new products, many of which are expected
to appear in the market soon.
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